PUBLICATIONS

SELECTED PUBLICATIONS

C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer.

Klümper N, Saal J, Berner F, Lichtensteiger C, Wyss N, Heine A, Bauernfeind FG, Ellinger J, Brossart P, Diem S, Schmid S, Joerger M, Frueh M, Ritter M, Hölzel M, Flatz L, Bald T.
J Immunother Cancer. 2022 Mar;10(3):e004024. doi: 10.1136/jitc-2021-004024.

Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma.
Yurchenko AA, Pop OT, Ighilahriz M, Padioleau I, Rajabi F, Sharpe HJ, Poulalhon N, Dreno B, Khammari A, Delord M, Alberti A, Soufir N, Battistella M, Mourah S, Bouquet F, Savina A, Besse A, Mendez-Lopez M, Grange F, Monestier S, Mortier L, Meyer N, Dutriaux C, Robert C, Saiag P, Herms F, Lambert J, de Sauvage FJ, Dumaz N, Flatz L, Basset-Seguin N, Nikolaev SI.
Clin Cancer Res. 2022 Apr 1;28(7):1422-1432. doi: 10.1158/1078-0432.CCR-21-3764.

Viral vector-mediated reprogramming of the fibroblastic tumor stroma sustains curative melanoma treatment.

Ring SS, Cupovic J, Onder L, Lütge M, Perez-Shibayama C, Gil-Cruz C, Scandella E, De Martin A, Mörbe U, Hartmann F, Wenger R, Spiegl M, Besse A, Bonilla WV, Stemeseder F, Schmidt S, Orlinger KK, Krebs P, Ludewig B, Flatz L.

Nat Commun. 2021 Aug 5;12(1):4734. doi: 10.1038/s41467-021-25057-w.

Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival.

Berner F, Niederer R, Luimstra JJ, Pop OT, Jochum AK, Purde MT, Hasan Ali O, Bomze D, Bauer J, Freudenmann LK, Marcu A, Wolfschmitt EM, Haen S, Gross T, Dubbelaar ML, Abdou MT, Baumgaertner P, Appenzeller C, Cicin-Sain C, Lenz T, Speiser DE, Ludewig B, Driessen C, Jörger M, Früh M, Jochum W, Cozzio A, Rammensee HG, Walz J, Neefjes J, Flatz L.

Oncoimmunology. 2021 Nov 27;10(1):2006893. doi: 10.1080/2162402X.2021.2006893.

Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.

Purde MT, Niederer R, Wagner NB, Diem S, Berner F, Hasan Ali O, Hillmann D, Bergamin I, Joerger M, Risch M, Niederhauser C, Lenz TL, Früh M, Risch L, Semela D, Flatz L.

J Cancer Res Clin Oncol. 2021 Dec 7. doi: 10.1007/s00432-021-03870-6.

Recombinant lymphocytic choriomeningitis virus-based vaccine vector protects type I interferon receptor deficient mice from viral challenge.

Krolik M, Csepregi L, Hartmann F, Engetschwiler C, Flatz L.

Vaccine. 2021 Feb 22;39(8):1257-1264. doi: 10.1016/j.vaccine.2021.01.047.

Heterologous Prime Boost Vaccination Induces Protective Melanoma-Specific CD8+ T Cell Responses.

Ring SS, Królik M, Hartmann F, Schmidt E, Ali OH, Ludewig B, Kochanek S, Flatz L.

Mol Ther Oncolytics. 2020 Oct 10;19:179-187. doi: 10.1016/j.omto.2020.10.001.

Severe COVID-19 is associated with elevated serum IgA and antiphospholipid IgA-antibodies.

Hasan Ali O, Bomze D, Risch L, Brugger SD, Paprotny M, Weber M, Thiel S, Kern L, Albrich WC, Kohler P, Kahlert CR, Vernazza P, Bühler PK, Schüpbach RA, Gómez-Mejia A, Popa AM, Bergthaler A, Penninger JM, Flatz L.

Clin Infect Dis. 2020 Sep 30:ciaa1496. doi: 10.1093/cid/ciaa1496.

Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients.

Hasan Ali O, Berner F, Ackermann CJ, Ring SS, Moulin A, Müller J, Markert E, Pop OT, Müller S, Diem S, Hundsberger T, Flatz L.

Cancer Immunol Immunother. 2021 Feb;70(2):563-568. doi: 10.1007/s00262-020-02693-7.

Genomic profiling of late-onset basal cell carcinomas from two brothers with nevoid basal cell carcinoma syndrome.

Hasan Ali O, Yurchenko AA, Pavlova O, Sartori A, Bomze D, Higgins R, Ring SS, Hartmann F, Bühler D, Fritzsche FR, Jochum W, Navarini AA, Kim A, French LE, Dermitzakis E, Christiano AM, Hohl D, Bickers DR, Nikolaev SI, Flatz L.

J Eur Acad Dermatol Venereol. 2021 Feb;35(2):396-402. doi: 10.1111/jdv.16767.

BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors.

Hasan Ali O, Bomze D, Ring SS, Berner F, Fässler M, Diem S, Abdou MT, Hammers C, Emtenani S, Braun A, Cozzio A, Mani B, Jochum W, Schmidt E, Zillikens D, Sadik CD, Flatz L.

J Am Acad Dermatol. 2020 Apr;82(4):854-861. doi: 10.1016/j.jaad.2019.08.045.

Association Between Immune-Related Adverse Events During Anti-PD-1 Therapy and Tumor Mutational Burden.

Bomze D, Hasan Ali O, Bate A, Flatz L.

JAMA Oncol. 2019 Aug 22;5(11):1633-5. doi: 10.1001/jamaoncol.2019.3221.

Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer.

Berner F, Bomze D, Diem S, Ali OH, Fässler M, Ring S, Niederer R, Ackermann CJ, Baumgaertner P, Pikor N, Cruz CG, van de Veen W, Akdis M, Nikolaev S, Läubli H, Zippelius A, Hartmann F, Cheng HW, Hönger G, Recher M, Goldman J, Cozzio A, Früh M, Neefjes J, Driessen C, Ludewig B, Hegazy AN, Jochum W, Speiser DE, Flatz L.

JAMA Oncol. 2019 Jul 1;5(7):1043-1047. doi: 10.1001/jamaoncol.2019.0402.

Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients.

Fässler M, Diem S, Mangana J, Hasan Ali O, Berner F, Bomze D, Ring S, Niederer R, Del Carmen Gil Cruz C, Pérez Shibayama CI, Krolik M, Siano M, Joerger M, Recher M, Risch L, Güsewell S, Risch M, Speiser DE, Ludewig B, Levesque MP, Dummer R, Flatz L.

J Immunother Cancer. 2019 Feb 20;7(1):50. doi: 10.1186/s40425-019-0523-2.

Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors.

Hasan Ali O, Berner F, Bomze D, Fässler M, Diem S, Cozzio A, Jörger M, Früh M, Driessen C, Lenz TL, Flatz L.

Eur J Cancer. 2019 Jan;107:8-14. doi: 10.1016/j.ejca.2018.11.009.

Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors.

Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment.

Diem S, Fässler M, Bomze D, Ali OH, Berner F, Niederer R, Hillmann D, Mangana J, Levesque MP, Dummer R, Risch L, Recher M, Risch M, Flatz L.

J Immunother. 2019 Apr;42(3):89-93. doi: 10.1097/CJI.0000000000000255.

Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment.

Diem S, Fässler M, Hasan Ali O, Siano M, Niederer R, Berner F, Roux GA, Ackermann CJ, Schmid S, Güsewell S, Früh M, Flatz L.

Cancer Manag Res. 2018 Nov 8;10:5537-5544. doi: 10.2147/CMAR.S179767.